Evidence map›Paper›PMID 42220608›Full record

ReviewMaterials today. Bio2026

Precision nanomedicine for lung metastatic osteosarcoma: challenges, therapeutic strategies, and perspectives.

Haozheng Li, Jing Luo, Qianli Wang, Yang Zhang, Qiujiang Li, Xiaoyong Wang, Gang Liu, Changrong Shi, Wei Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Haozheng LiDepartment of Orthopedics, Sichuan Provincial People's Hospital & Sichuan Academy of Medical Sciences & Affiliated Hospital of University of Electronic Science and Technology, Chengdu, 610072, China.
Jing LuoDepartment of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Qianli WangDepartment of Orthopedics, Sichuan Provincial People's Hospital & Sichuan Academy of Medical Sciences & Affiliated Hospital of University of Electronic Science and Technology, Chengdu, 610072, China.
Yang ZhangState Key Laboratory of Vaccines for Infectious Diseases, Xiang an Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, Fujian Engineering Research Center of Molecular Theranostic Technology, Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China.
Qiujiang LiDepartment of Orthopedics, Sichuan Provincial People's Hospital & Sichuan Academy of Medical Sciences & Affiliated Hospital of University of Electronic Science and Technology, Chengdu, 610072, China.
Xiaoyong WangState Key Laboratory of Vaccines for Infectious Diseases, Xiang an Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, Fujian Engineering Research Center of Molecular Theranostic Technology, Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China.
Gang LiuState Key Laboratory of Vaccines for Infectious Diseases, Xiang an Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, Fujian Engineering Research Center of Molecular Theranostic Technology, Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China.
Changrong ShiDepartment of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117599, Singapore.
Wei ZhangDepartment of Orthopedics, Sichuan Provincial People's Hospital & Sichuan Academy of Medical Sciences & Affiliated Hospital of University of Electronic Science and Technology, Chengdu, 610072, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung metastatic osteosarcoma (LM-OS) remains the leading cause of mortality in patients with osteosarcoma and is poorly controlled by current therapeutic regimens. The limited efficacy of conventional treatments is closely related to the complex biological features of metastatic lesions, including marked tumor heterogeneity, restrictive microenvironmental conditions, immune suppression, and emerging neural involvement within the lung niche. In recent years, nanomedicine has been increasingly explored as a mean to improve drug delivery and therapeutic effectiveness in LM-OS. A range of nanocarrier strategies has been developed to enhance metastatic targeting, modulate the tumor microenvironment, and integrate multiple therapeutic functions. In this review, we summarize recent advances in nanomedicine for LM-OS using a barrier-oriented and disease-matched framework. Representative nanocarrier platforms designed to address heterogeneity, immune clearance, limited metastatic accessibility, and tumor-nerve interactions are discussed, together with the underlying biological considerations. Current translational challenges, including safety, manufacturability, and limitations of existing preclinical models, are also examined, and perspectives on future directions for nanomedicine-based treatment of LM-OS are provided. By anchoring nanocarrier design to the biological logic of LM-OS, this review aims to provide a conceptual roadmap for developing clinically translatable precision nanotherapies.

Indexed as

Lung metastatic osteosarcomaMetastatic microenvironmentNanomedicineTargeted drug deliveryTumor-nerve interaction

Identifiers

PMID42220608
PMCPMC13218267

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.